A Study To Assess The Effect Of Pyridoxine Supplementation In Preventing Migraine Attacks

A Randomized Controlled Trial To Study The Effect Of Pyridoxine As Adjuvant In Prophylaxis Of Migraine.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/07/014731

Enrollment

100

Registered

2018-07-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Migraine Health Condition 2: G43- Migraine

Interventions

Intervention1: Pyridoxine: Pyridoxine 80mg once daily for a period of six months along with standard drugs used in prophylaxis of Migraine. Standard therapy alone will be continued for another 3 month

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed as chronic migraine and on regular prophylaxis 6months or more Patients willing to give a written informed consent

Exclusion criteria

Exclusion criteria: Patients with headache other than migraine Patients with peripheral neuropathy or photosensitivity Patients with major systemic illness Patients taking vitamin supplements

Design outcomes

Primary

Measure	Time frame
reduction of MIDAS scoreTimepoint: 9 Months	—

Secondary

Measure	Time frame
The tolerability of the study drug will be assessed in migraine patients clinicallyTimepoint: tolerability of the intervention drug pyridoxine for the period of 6 months and 3 months follow up	—

Countries

India

Contacts

Public ContactDr N Caroline Devakirubai

Chengalpattu Medical College

vijayapaed@gmail.com9444728805

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026